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Objectives The purpose of this study was to investigate long-term outcomes of freedom from atrial fibrillation (AF) after pulmo-
nary vein (PV) isolation using cryoballoon ablation with balloon-size selection based on individual PV diameters.
Background Data are lacking on long-term outcomes from cryoablation and on the most effective balloon size.
Methods This was a prospective observational study involving 605 consecutively enrolled patients with symptomatic paroxys-
mal AF (n  579) or persistent AF. Cryoballoon size was based on magnetic resonance imaging and/or conventional
angiograms. Patients were followed up every 3 months during the first year after discharge and every 6 months in the
second year. After 24 months, follow-up was on an outpatient basis with documented AF episodes recorded.
Results The PV isolation was achieved without touch-up in 91.1% of patients, using the smaller balloon in 26.7%, the larger
balloon in 25.6%, and both balloons in 47.7% of patients. Follow-up data for 12 months (median 30 months; inter-
quartile range 18 to 48 months) were available for 451 patients, 278 (61.6%) of whom were free of AF recurrence
with no need for repeat procedures after the 3-month blanking period. Rates of freedom from AF after 1, 2, and 3
repeat procedures (using cryoballoon or radiofrequency ablation with similar success rates) were 74.9%, 76.2%, and
76.9%, respectively. Use of the smaller balloons or both balloons produced the highest rates of long-term freedom
from AF. Phrenic nerve palsy occurred in 12 patients (2%), resolving within 3 to 9 months.
Conclusions Rates of long-term freedom from AF after cryoballoon ablation are similar to those reported for radiofrequency
ablation. A choice between balloons may improve outcomes. (J Am Coll Cardiol 2013;61:1707–12) © 2013 by
the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.033Ablation procedures for circumferential pulmonary vein
isolation (PVI) by encircling the pulmonary vein (PV)
antrum have become the therapy of choice for drug-
refractory symptomatic focal atrial fibrillation (AF) (1), with
a continual increase in the number of procedures performed
annually (2). The majority of these procedures are carried
out with radiofrequency energy, but the use of cryoballoon
ablation is growing rapidly.
Most published cryoballoon studies have focused on
12-month outcomes (4–6), and current consensus guide-
From the Department of Cardiology, Heart and Diabetes Center North Rhine-
Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany. This work was
supported by an unrestricted grant from Medtronic. The sponsor had no influence on
the generation of the protocol, study conduct, data analysis, and interpretation, or on
the content and production of the manuscript. Dr. Vogt has received speaker’s
honoraria and honoraria for advisory board meetings from Medtronic. Drs. Nölker,
Gutleben, and Heintze have received speaker’s honoraria from Medtronic. All other
authors have reported they have no relationships relevant to the contents of this paper
to disclose.o
Manuscript received May 30, 2012; revised manuscript received September 11,
2012, accepted September 11, 2012.lines note the need for follow-up data beyond 12 months
from large patient populations (7,8). We conducted a
prospective, large-scale, long-term investigation into the
outcomes of cryoablation in consecutively enrolled patients
with AF. The choice between the 23-mm and 28-mm
balloons was made for individual veins on the basis of the
anatomies of the PV ostia. We also included the option of
using 2 balloon sizes in the same patient.
See page 1724
Methods
This was a prospective observational study involving 605
patients enrolled consecutively at our institute. All patients
provided informed consent, and the study was approved by
the local institutional ethics committee.
Enrolled patients had symptomatic paroxysmal AF, defined
as per Heart Rhythm Society (HRS)/European Heart Rhythm
Association (EHRA) consensus guidelines (8), with a history
f failed treatment with antiarrhythmic drugs class Ic and/or III.
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Long-Term Outcomes After Cryoballoon Ablation April 23, 2013:1707–12Exclusion criteria were as pub-
lished previously (4). Transesoph-
ageal echocardiography was per-
formed on all candidates to
exclude the presence of thrombi.
Ablation procedures and choice
of balloon size followed what has
been described previously (4).
Any phenprocoumon anticoagu-
lation therapy was continued,
with a target international nor-
malized ratio of 2.0 to 3.0. A
double transseptal puncture was
performed to access the left atrium (LA) in the first 253
patients. In the succeeding patients, the LA was accessed by
a single transseptal puncture from the right femoral vein,
and a steerable 12-F inner diameter sheath (FlexCath,
Medtronic, Minneapolis, Minnesota) was employed. Bal-
loon occlusion was assessed with the help of 50% diluted
contrast medium injected into the PV and confirmed within
the first minute of cryoenergy application (Fig. 1).
In the 518 patients treated between 2005 and 2010, a
20-polar Lasso catheter (Biosense Webster, Diamond Bar,
Figure 2 Patient Flow
Schematic representation of the flow of atrial fibrillation (AF) patients through the
procedures were treated in the early study phase using the Lasso catheter. *Procedu
Abbreviations
and Acronyms
AF  atrial fibrillation
ECG  electrocardiography
LA  left atrium
LS  left superior
PNP  phrenic nerve palsy
PV  pulmonary vein
PVI  pulmonary vein
isolationFigure 1 Example of Successful Balloon Occlusion
Guided by the Achieve Catheter
Fluoroscopy image of the inflated 28-mm balloon at the
antrum of the left superior pulmonary vein with the Achieve.study. All 53 patients who needed touch-up
ral data missing for 1 patient. PVI  pulmonary vein isolation.
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April 23, 2013:1707–12 Long-Term Outcomes After Cryoballoon AblationCalifornia) was placed in the LA to map signals before and
after ablation at the ostial sides of PVs. Starting in 2010, the
Achieve mapping catheter (Medtronic) was employed in-
stead to enable mapping during and after each freezing
procedure (n  87). Freezing times were 2  360 s for each
ein, 3  300 s for left superior (LS) PVs.
Sustained PVI was confirmed 30 min after the initial
solation. For difficult verifications, namely, because of large
ar-field potentials of the LA, exit block was confirmed by
acing within the PV ostium monitored with the Lasso or
chieve catheter. In 53 patients in the early cohort,
ouch-up of remaining gaps was performed with the 8-mm
ip Freezor MAX focal cryoablation catheter (Medtronic
ryocath). In all later patients, residual potentials were
liminated with additional balloon freezes.
Post-ablation treatment was as described previously (4).
uring a blanking period of 3 months, antiarrhythmic treat-
ent with the former ineffective drug was allowed to facilitate
aintenance of sinus rhythm. Patients who failed 3 repeat
blation attempts were put on antiarrhythmic drug regimens.
Patients were scheduled for follow-up visits every 3
onths during the first year after discharge and every 6
onths in the second year. After 24 months, follow-up was
n an outpatient basis with documented AF episodes
ecorded.
In the first 109 patients, 1 or more magnetic resonance
maging/computed tomography scans were performed dur-
ng the first 12 months to assess PV diameters and to
xclude PV stenosis. The procedure was found unnecessary
nd discontinued for subsequent patients. Seven-day Holter
lectrocardiography (ECG) recordings were obtained at
ach visit for the first 12 months of follow-up, including the
Baseline CharacteristicsTable 1 Baseline Characteristics
n 605
Women 199 (32.9)
Age, yrs 59.0 11
Paroxysmal AF 579 (95.7)
Recently developed persistent AF 26 (4.3)
CHADS2 score 0.7 0.8
Idiopathic AF 276 (45.6)
Mild structural heart disease 76 (12.6)
Arterial hypertension 252 (41.7)
Mean duration of AF, months 50 (24–96)
LA diameter, mm 42.1 5.6
Mean PV diameter, mm 19.3 3.4
Left superior PV 20.2 3.5
Left inferior PV 17.6 3.0
Left common ostium 26.3 3.0
Right superior PV 20.4 3.1
Right inferior PV 18.6 3.4
LVEF, % 57.1 4.0
Values are n, n (%), mean  SD, or median (interquartile range).
AF  atrial fibrillation; CHADS2 score  stroke risk score (congestive heart failure, hyperten-
sion, age 75 years, diabetes mellitus; prior stroke); LA  left atrium; LVEF  left ventricular
jection fraction; PV  pulmonary vein.rst 12 months after repeat procedures (8). tndpoints. The primary endpoint was successful isolation
f all 4 PVs, defined as confirmed unidirectional entrance
lock complete with absence of PV spikes. Secondary
ndpoints were the recurrence of AF during follow-up,
rocedural data, complications, and the time to successful
VI. Recurrence was defined as an episode of AF 30 s
ocumented on 7-day Holter ECG, or any ECG-
ocumented AF during follow-up. No Holter monitoring
as included in the protocol after the first 12 months. Safety
ndpoints were the occurrence of PV stenosis or atri-
esophageal fistula and peri-interventional safety.
tatistical analysis. Kaplan-Meier univariate analysis was
sed to estimate AF-free survival. Continuous data are
epresented as mean  SD or median and interquartile
ange, as appropriate. The chi-square test was employed
ost-hoc for comparisons of success and recurrence rates
etween different balloon sizes and an unpaired t test for
ost-hoc comparisons of procedure and fluoroscopy times
etween balloon sizes. The criterion for statistical signifi-
ance was set to p  0.05.
esults
total of 605 patients were enrolled consecutively between
uly 2005 and August 2011. The flow of patients is shown
n Figure 2. Demographic criteria are shown in Table 1. In
6 patients, persistent AF developed between the schedul-
ng and carrying out of the ablation procedure, and they
emained in the study population.
The PVI was achieved without the need for focal touch-
p with Freezor MAX in 551 patients (91.1%). An average
f 2.4  1.0 applications were needed to achieve PVI. Total
rocedure and fluoroscopy times with the 28-mm balloon,
3-mm balloon, and 2 balloons, respectively, are shown in
able 2. There was a steep learning curve (Fig. 3).
Of the 551 patients treated with cryoballoon ablation
nly, 147 patients (26.7%) were treated with the 23-mm
alloon, and 141 patients (25.6%) with the 28-mm balloon.
wo balloons were employed in 263 patients (47.7%),
rimarily in cases of rapid reconduction despite good
cclusion in younger patients with greater cardiac output,
hen hockey-stick or pull-down maneuvers were unsuccess-
ul, in conically shaped venous openings, insufficient occlu-
Procedure and Fluoroscopy TimesWith Diff re t Ball ons and 2 Balloons,Respectively, for Patients With Foll w-UpDa a Af er 3-M nth Blanking Peri d (n  553)*
Table 2
Procedure and Fluoroscopy Times
With Different Balloons and 2 Balloons,
Respectively, for Patients With Follow-Up
Data After 3-Month Blanking Period (n  553)*
Procedure Total Procedure Time, Min Fluoroscopy Time, Min
All procedures 156 (131–189) 25.2 (19.6–32.2)
23-mm balloon only 142 (116–177) 23.0 (18.1–29.1)
28-mm balloon only 152 (129–198) 25.1 (20.2–36.4)
2 balloons 165 (141–191) 26.5 (20.8–32.7)
Values are median (interquartile range). For the comparisons 23-mm balloon versus all other
methods, p 0.005; for the comparison 28-mm balloon versus 2 balloons, p NS. *For 1 patient,
he balloon size was not recorded.
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incompletely isolated right inferior PVs.
Recurrences of AF within the blanking period were
documented for 46 patients, 23 of whom had no further
recurrences and did not undergo repeat procedures.
Freedom from AF during long-term follow-up. Twenty
patients were lost to follow-up. One patient died before the
first follow-up visit, and 2 patients died during follow-up.
No death was associated with any of the procedures.
Follow-up data after the 3-month blanking period (median
24 months; interquartile range: 12 to 42 months; mean 28.2
19.0 months) were available for 554 patients (91.6%). Rates
of freedom from AF were significantly higher using the
23-mm balloon or 2 balloons than using only the 28-mm
balloon (Fig. 4A). This difference remained significant
when the 53 patients who received focal touch up with
Freezor MAX were excluded from the analysis.
Long-term follow-up data 12 months (median 30
months; interquartile range: 18 to 48 months; mean 33.4 
17.3 months) were available for 451 patients. Actively solicited
data on vital status at the end of follow-up were obtained for
191 patients. Of the 451 patients, 278 (61.6%) remained free
of AF with no need for repeat procedures after the blanking
period (Fig. 4B). The percentages of patients free of AF after
1, 2, and 3 repeat procedures, respectively, after the blanking
period were 74.9%, 76.2%, and 76.9%. The first repeat proce-
dure utilized cryoballoon in 79 cases and radiofrequency in 28
cases. Further repeat procedures were predominantly radiofre-
quency ablations (13 of 18 procedures). Success rates were
similar with both technologies.
The rate of decline in freedom from documented AF
recurrences was steepest during the first 12 months of
follow-up (Fig. 4B). A total of 124 recurrences (22.4% of
patients) were documented between months 4 and 12, and
Figure 3 Procedure and Fluoroscopy Times
Blue bars indicate procedure time, and red bars indicate fluoroscopy time for diffe
For all comparisons between groups, p  0.05.59 recurrences (10.6%) were documented after month 12.Complications. Acute adverse events are shown in Table 3.
Phrenic nerve palsy (PNP) occurred in 12 patients (2%) and
resolved within 3 to 9 months. There was no case of chronic
PNP. Hemoptysis with hematoma or edema around PVs
was observed in 10 cases, all of which healed within 10 days.
Patients remained free of hemoptysis during the follow-up
period.
Discussion
This study provides data on the long-term effectiveness and
safety of cryoballoon ablation in a large representative
cohort of patients with paroxysmal AF. The mean docu-
mented follow-up time of 33.4 17.3 months is the longest
reported to date for PVI with cryoballoon ablation.
Long-term success rates of PVI procedures. Rates of
freedom from AF without and with repeat ablations after
the initial 3-month blanking period were 61.6% and 76.9%,
respectively, highly similar to rates achieved with radiofre-
quency ablation (9,10). Rates of freedom from AF could be
improved by optimizing the choice of balloon size to fit the
PV anatomies in each individual case.
Most recurrences occurred within the first 12 months, as
previously reported both for radiofrequency ablation and for
cryoablation over shorter follow-up periods (5). That may be
due in part to the changes in follow-up examinations.
Both in our study and in the 5-year follow-up analysis of
radiofrequency ablation (10), 7-day Holter ECG moni-
toring was not routinely performed after 12 months of
follow up. A direct comparison between cryoballoon and
radiofrequency ablation technologies is conducted in the
on-going prospective, randomized FIRE AND ICE trial
(NCT01490814).
The similarities in outcomes from cryoballoon and radio-
onsecutive groups of patients. Lines represent standard deviation.rent cfrequency ablation may hint at limitations inherent in PVI.
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April 23, 2013:1707–12 Long-Term Outcomes After Cryoballoon AblationThe first repeat procedures, whether cryoballoon or radio-
frequency ablation, increased the percentage of recurrence-
free patients by 13.3 percentage points. Subsequent repeat
procedures increased rates by a fraction of this amount. Two
conclusions might be drawn. First, cryoablation is an equally
valid alternative to radiofrequency for repeat procedures.
Second, lack of success is most likely due to underlying
pathologies rather than to the method used. If so, the
challenge would be to identify in advance this subgroup of
patients who are particularly resistant to PVI and consider
alternative treatments, rather than attempt incremental
Figure 4 Rates of Freedom From AF
(A) Rates of freedom from atrial fibrillation (AF) in all patients with follow-up data
tion of balloon size. (B) Kaplan-Meier curves showing long-term rates of freedom
the last ablation attempt (including redos within the blanking period), respectiv
(blue lines). Thin vertical lines  mean follow-up times for the 2 groups.procedural improvements.Choice of optimal cryoballoon size. Some groups have
advocated the 28-mm “single big balloon” methodology
(11,12), but there are concerns that improved safety with
the larger balloon may come at the cost of lower success rates
(13,14). By providing tissue contact closer to the equatorial
region of the balloon, smaller balloons may produce lower
temperatures than the 28-mm balloon. In our hands, recur-
rence rates were indeed highest with the larger balloon.
However, the larger balloon should be the first choice to create
an antral isolation in large veins and common ostia, as the
smaller 23-mm balloon may cause ostial isolation and jeopar-
53). One patient was excluded from the analysis because of lack of documenta-
AF after 1 ablation attempt (no redos within the blanking period) and after
the cohorts followed up for 3 months (red lines) and 12 months(n  5
from
ely, indize lung tissue, esophagus, and PV diameter. In our center,
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use 2 balloon sizes in the same patient.
Safety findings. We recorded very few PNPs, despite fre-
quent use of the smaller 23-mm balloon. We found 10 cases of
bronchial erosion and hemoptysis. Although this corresponds
to an incidence rate of 2%, and all cases healed within 10
days, operators should be aware of the potential risk.
Study limitations. This was a single-center study with
possibly smaller differences between individual operators
than in multicenter studies. Operator familiarity and pref-
erences for 1 balloon size over the other may have influenced
the results. Follow-up became less rigorous after the first 12
months. Furthermore, the equipment changed during the
study, notably the discontinuation of Freezor MAX after
the first 53 patients and the introduction of the Achieve
catheter for the last 83 patients.
Conclusions
In our clinical experience, long-term rates of freedom from
AF over several years after cryoballoon ablation appear
comparable to those with radiofrequency energy ablation,
although randomized, controlled studies would be needed
to demonstrate this conclusively. Selecting the appropriate
balloon size for each individual vein anatomy to ensure the
best fit increases long-term success rates, but there is a
trade-off in increased procedural risk with the smaller
balloon that should be taken into account.
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